NCT02500485 is a Phase 1 clinical trial of SHR3824, SP2086 in Type 2 Diabetes, sponsored by Jiangsu HengRui Medicine Co., Ltd..

Who is sponsoring NCT02500485?

NCT02500485 is sponsored by Jiangsu HengRui Medicine Co., Ltd..

What drugs are being tested in NCT02500485?

Interventions in NCT02500485: SHR3824, SP2086.

What condition does NCT02500485 study?

NCT02500485 studies Type 2 Diabetes.

Is NCT02500485 still recruiting?

NCT02500485 is currently status unknown. Last updated 23 November 2015.

Last reviewed 2015-11-23 · How we verify

NCT02500485

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Drug Interaction Study of Henagliflozin and Retagliptin in Healthy Subjects

Status unknown Phase 1 Last updated 23 November 2015

What this trial tests

Phase 1 trial testing SHR3824, SP2086 in Type 2 Diabetes in 12 participants. Status unknown.

Timeline

1 May 2015

Primary endpoint
1 July 2015

Quick facts

Lead sponsor	Jiangsu HengRui Medicine Co., Ltd.
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	1 May 2015
Primary completion	1 July 2015
Sites	1 location across China

Drugs / interventions tested

SHR3824, SP2086 — full drug profile →

Conditions studied

Type 2 Diabetes — all drugs for Type 2 Diabetes →

Sponsor

Jiangsu HengRui Medicine Co., Ltd. — full company profile →

Who can join

Adults 18 to 45, male only, with Type 2 Diabetes. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

The maximum plasma concentration (Cmax) of SHR3824.
Time frame: At protocol-specified times up to Day 14 and Day 18.
Cmax (a measure of the body's exposure to SHR3824) will be compared before and after administration of multiple doses of SP2086.
The area under the plasma concentration-time curve (AUC) of SHR3824.
Time frame: At protocol-specified times up to Day 14 and Day 18.
AUC (a measure of the body's exposure to SHR3824) will be compared before and after administration of multiple doses of SP2086.
The maximum plasma concentration (Cmax) of SP2086.
Time frame: At protocol-specified times up to Day 4 and Day 18.
Cmax (a measure of the body's exposure to SP2086) will be compared. before and after administration of multiple doses of SHR3824
The area under the plasma concentration-time curve (AUC) of SP2086.
Time frame: At protocol-specified times up to Day 4 and Day 18.
AUC (a measure of the body's exposure to SP2086) will be compared before and after administration of multiple doses of SHR3824.
The number of volunteers with adverse events as a measure of safety and tolerability.
Time frame: Up tp day 18.

Sponsor's own description

The purpose of the study is to investigate the potential interaction between multiple oral doses of SHR3824 and multiple oral doses of SP2086 in healthy adult volunteers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Type 2 Diabetes

Currently open trials in the same condition.

NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
NCT07254689 — The Food for Health Study · NA · recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting

Other Jiangsu HengRui Medicine Co., Ltd. trials

Trials by the same sponsor.

NCT07252921 — Safety and Efficacy of HRS-9190 Compared to Rocuronium for Tracheal Intubation in Adults · Phase 2 · completed
NCT07142850 — A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Bolus and Infusion HR · Phase 1 · completed
NCT07073157 — Effect of HRS-8427 for Injection on the Pharmacokinetics of Furosemide and Metformin in Healthy Subjects。 · Phase 1 · completed
NCT07076459 — A Comparative Pharmacokinetic Study of Single-Dose Administration of HR091506 Tablets From Different Batches in Healthy · Phase 1 · completed
NCT07049107 — Pharmacokinetics Impact of HRS-8427 on Bupropion and Midazolam in Healthy Subjects · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02500485 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jiangsu HengRui Medicine Co., Ltd.
Last refreshed: 23 November 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02500485.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing